Avidity Partners Management »

Scynexis shares owned by Avidity Partners Management

Quarter-by-quarter ownership of Scynexis shares owned by Avidity Partners Management from 13F filings

Historical chart of Avidity Partners Management investment in Scynexis

Tip: Access up to 7 years of quarterly data

All positions including Scynexis held by Avidity Partners Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Scynexis by Avidity Partners Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $1.1M 260k 4.07

More positions owned by Avidity Partners Management

Dianthus Therapeutics (DNTH)
Cg Oncology (CGON)
Oruka Therapeutics (ORKA)
Jade Biosciences Com New (JBIO)
Enliven Therapeutics (ELVN)
Perspective Therapeutics Com New (CATX)
Aktis Oncology (AKTS)
Palvella Therapeutics Inc Ne (PVLA)
Mobia Med Common Stock
Repligen Corporation (RGEN)
Immunic Com New (IMUX)
Senseonics Hldgs (SENS)
Karyopharm Therapeutics Com New (KPTI)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Dex (DXCM)

View all positions for Avidity Partners Management

Top funds holding Scynexis

Dr. Jeffrey R. Jay, M.D.
Squadron Capital Management
Adage Capital Partners GP
Propel Bio Management
Woodline Partners
Vanguard Capital Management
Avidity Partners Management
Kingdon Capital Management
Millennium Management
Heights Capital Management
DAFNA Capital Management
Empery Asset Management
Acadian Asset Management
Geode Capital Management
Renaissance Technologies

View all funds holding Scynexis